April 13 (Reuters) - Kalytera Therapeutics Inc KALY.V :
* CLINICAL PROGRAMS IN BONE DISEASE
* COMPANY TO FOCUS RESOURCES ON GVHD AND PAIN PROGRAMS
* DETERMINED INVESTMENTS OF TIME, RESOURCES IN THESE PROGRAMS NOT APPROPRIATE GIVEN OTHER OPPORTUNITIES IN DEVELOPMENT PIPELINE
* TERMINATED PROGRAMS WERE EVALUATING THREE SYNTHETIC ENDOCANNABINOID COMPOUNDS, KAL436, KAL439 AND KAL671
* CLINICAL PROGRAMS DOES NOT REFLECT A NEGATIVE ASSESSMENT OF COMPOUNDS LICENSED FROM YISSUM
* DECISION TO TERMINATE THESE PROGRAMS IS PART OF OVERALL STRATEGY TO FOCUS ON DEVELOPMENT OF CANNABINOID THERAPEUTICS